Effects of Primary Sclerosing Cholangitis on Risks of Cancer and Death in People With Inflammatory Bowel Diseases, Based on Sex, Race, and Age

HepatologyInflammatory Bowel Disease

Effects of Vedolizumab in Patients with Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases

Clin Gastroenterol Hepatol.

Lynch KD, Chapman RW, Keshav S, Montano-Loza AJ, Mason AL, Kremer AE, Vetter M, de Krijger M, Ponsioen CY, Trivedi P, Hirschfield G, Schramm C, Liu CH, Bowlus CL, Estes DJ, Pratt D, Hedin C, Bergquist A, de Vries AC, Janneke van der Woude C, Yu L, Assis DN, Boyer J, Ytting H, Hallibasic E, Trauner M, Marschall HU, Daretti LM, Marzioni M, Yimam KK, Perin N, Floreani A, Beretta-Piccoli BT, Rogers JK, International Primary Sclerosing Cholangitis Study Group (IPSCSG)., Levy C

doi: 10.1016/j.cgh.2019.05.013.

COMMENTED

Inflammatory Bowel Disease

Vedolizumab therapy is ineffective for primary sclerosing cholangitis in patients with inflammatory bowel disease: A GETAID multicentre cohort study

J Crohns Colitis.

Caron B, Peyrin-Biroulet L, Pariente B, Bouhnik Y, Seksik P, Bouguen G, Caillo L, Laharie D, Carbonnel F, Altwegg R, Reenaers C, Serrero M, Trang-Poisson C, Nancey S, Filippi J, Abitbol V, Savoye G, Vuitton L, Viennot S, Fumery M, Reymond M, Bronowicki JP, Reimund JM, Amiot A, GETAID.

doi: 10.1093/ecco-jcc/jjz088.

Gastrointestinal CancerInflammatory Bowel Disease

Inflammatory bowel disease and risk of small bowel cancer: a binational population-based cohort study from Denmark and Sweden

Gut.

Axelrad JE, Olén O, Sachs MC, Erichsen R, Pedersen L, Halfvarson J, Askling J, Ekbom A, Sørensen HT, Ludvigsson JF

doi: 10.1136/gutjnl-2020-320945.

Inflammatory Bowel Disease

Clinical characteristics, associated malignancies and management of primary sclerosing cholangitis in inflammatory bowel disease patients: A multicenter retrospective cohort study

J Crohns Colitis.

Guerra I, Bujanda L, Castro J, Merino O, Tosca J, Camps B, Gutiérrez A, Gordillo Ábalos J, de Castro L, Iborra M, Carbajo AY, Taxonera C, Rodríguez-Lago I, Mesonero F, de Francisco R, Gómez-Gómez GJ, Chaparro M, Tardillo CA, Rivero M, Algaba A, Martín Arranz E, Cañete F, Vicente R, Sicilia B, Antolín B, Prieto V, Márquez L, Benítez JM, Camo P, Piqueras M, Gargallo CJ, Hinojosa E, Huguet JM, Pérez Calle JL, Van Domselaar M, Rodriguez C, Calvet X, Muñoz-Villafranca C, García-Sepulcre MF, Munoz-Garrido P, Fernández-Clotet A, Gómez Irwin L, Hernández S, Guardiola J, Sempere L, González Muñoza C, Hernández V, Beltrán B, Barrio J, Alba C, Moraleja I, López-Sanromán A, Riestra S, Martínez Montiel P, Garre A, Arranz L, García MJ, Martín Arranz MD, Corsino P, Arias L, Fernández-Salazar L, Fernández-Pordomingo A, Andreu M, Iglesias E, Ber Y, Mena R, Arroyo Villarino MT, Mora M, Ruiz L, López-Serrano P, Blazquez I, Villoria A, Fernández M, Bermejo F, Banales JM, Domènech E, Gisbert JP, Spanish GETECCU group (ENEIDA Project).

doi: 10.1093/ecco-jcc/jjz094.

RECOMMENDED

Inflammatory Bowel Disease

Cancer Risk in Inflammatory Bowel Disease: A 6-Year Prospective Multicenter Nested Case-Control IG-IBD Study

Inflamm Bowel Dis.

Biancone L, Armuzzi A, Scribano ML, Castiglione F, D'incà R, Orlando A, Papi C, Daperno M, Vecchi M, Riegler G, Fries W, Alvisi P, Meucci G, Mocciaro F, Rogai F, Festa S, Guidi L, Testa A, Spina L, Renna S, Viola A, Patturelli M, Di Mitri R, Frankovic I, Calabrese E, Petruzziello C, De Cristofaro E, Sena G, Ruffa A, Neri B, Rossi A, Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD).

doi: 10.1093/ibd/izz155.

Inflammatory Bowel Disease

Extracolonic cancer risk after total colectomy for inflammatory bowel disease: A population-based cohort study

J Crohns Colitis.

Mark-Christensen A, Erichsen R, Veres K, Laurberg S, Sørensen HT

doi: 10.1093/ecco-jcc/jjz199.

Inflammatory Bowel Disease

Effect of distance to specialist care for the diagnosis and disease outcome of inflammatory bowel disease in the Swiss inflammatory bowel disease cohort study

Therap Adv Gastroenterol.

Grob L, Bluemel S, Biedermann L, Fournier N, Rossel JB, Vavricka SR, Zeitz J, Rogler G, Stallmach A, Scharl M

doi: 10.1177/1756284819895217.

Inflammatory Bowel Disease

Systematic Review with Meta-analysis: The Impact of Co-occurring Immune-mediated Inflammatory Diseases on the Disease Course of Inflammatory Bowel Diseases

Inflamm Bowel Dis.

Attauabi M, Zhao M, Bendtsen F, Burisch J

doi: 10.1093/ibd/izaa167.

Inflammatory Bowel Disease

Hormone Therapy for Cancer is a Risk Factor for Relapse of Inflammatory Bowel Diseases

Clin Gastroenterol Hepatol.

Axelrad JE, Bazarbashi A, Zhou J, Castañeda D, Gujral A, Sperling D, Glass J, Agrawal M, Hong S, Lawlor G, Hudesman D, Chang S, Shah S, Yajnik V, Ananthakrishnan A, Khalili H, Colombel JF, Itzkowitz S, New York Crohn’s and Colitis Organization (NYCCO).

doi: 10.1016/j.cgh.

Related content

Effects of Vedolizumab in Patients with Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases

Vedolizumab therapy is ineffective for primary sclerosing cholangitis in patients with inflammatory bowel disease: A GETAID multicentre cohort study

Inflammatory bowel disease and risk of small bowel cancer: a binational population-based cohort study from Denmark and Sweden

Clinical characteristics, associated malignancies and management of primary sclerosing cholangitis in inflammatory bowel disease patients: A multicenter retrospective cohort study

Cancer Risk in Inflammatory Bowel Disease: A 6-Year Prospective Multicenter Nested Case-Control IG-IBD Study

Extracolonic cancer risk after total colectomy for inflammatory bowel disease: A population-based cohort study

Effect of distance to specialist care for the diagnosis and disease outcome of inflammatory bowel disease in the Swiss inflammatory bowel disease cohort study

Systematic Review with Meta-analysis: The Impact of Co-occurring Immune-mediated Inflammatory Diseases on the Disease Course of Inflammatory Bowel Diseases

Hormone Therapy for Cancer is a Risk Factor for Relapse of Inflammatory Bowel Diseases